NRX PHARMACEUTICALS INC

$3.14 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About NRX PHARMACEUTICALS INC

NRX Pharmaceuticals, Inc., formerly Big Rock Partners Acquisition Corp., is a patient-focused, clinical stage pharmaceutical company. The Company is focused on developing NRX-101. NRX-101 is an oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder and ZYESAMI (aviptadil), an intravenous and inhaled drug to treat respiratory failure in COVID-19. NRX-101 is designed to offer an oral, rapid-onset and sustained home-use therapy that can extend ketamine’s anti-suicidal benefit and reduce the side effects of ketamine. The Company combines D-cycloserine (DCS), a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, a 5-HT2a receptor antagonist. NRX-101 is in Phase III of clinical testing.

Stock Analysis

last close $3.31
1-mo return -40%
3-mo return -68.9%
avg daily vol. 1.35M
52-week high 64.2
52-week low 3.21
market cap. $195M
forward pe -
annual div. -
roe -5235%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 4.1%
baraka

Subscribe now for daily local and international financial news

Subscribe